Novo Holdings co-leads Hemab’s US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders

  • Novo Holdings created Hemab from inception and now co-leads significant financing with Nordic and US investors
  • Financing to advance pipeline of bispecific and monoclonal antibodies with prophylactic potential to avoid life-threatening bleeds
  • New management team led by Benny Sorensen

Copenhagen, Denmark and Boston, US – 22 July 2021 – Novo Holdings, a leading international life science investor, today announces that it has co-led alongside HealthCap and RA Capital Management a US$ 55M Series A financing in Hemab ApS (“Hemab”), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH